ABVC BioPharma (ABVC) vs Seres Therapeutics (MCRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Seres Therapeutics is the larger company by market cap ($26.4 million vs $26.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABVC | MCRB |
|---|---|---|
| Share price | $0.98 | $2.63 |
| Market cap | $26.16M | $26.42M |
| 1-day change | -2.00% | -3.31% |
| YTD return | -53.99% | — |
| 1-year return | -69.75% | — |
| 5-year return | -96.38% | — |
| EPS (TTM) | $-0.30 | $-2.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.33 | $29.98 |
| 52-week low | $0.707 | $2.42 |
| Distance from 52-week high | -70.54% | -91.23% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +546.39% |
| Average volume | 111.36K | 73.43K |
| Shares outstanding | 26.69M | 10.04M |
| Employees | 16 | 66 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ABVC BioPharma
ABVC stock →ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients.
Healthcare · Biotechnology · 16 employees
About Seres Therapeutics
MCRB stock →Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.
Healthcare · Biotechnology · 66 employees
ABVC vs MCRB FAQ
Which is bigger, ABVC BioPharma or Seres Therapeutics?
Seres Therapeutics (MCRB) is larger, with a market capitalization of $26.42M compared with $26.16M for ABVC BioPharma (ABVC).
Are ABVC BioPharma and Seres Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.